Treatment with metformin prevents TXNIP/NLRP3 inflammasome activation by suppressing ER stress in the adipose tissues of STZ-injected diabetic mice, thereby blocking diabetes-induced adipose dysfunction69. Here, TXNIP is linked to diabetes mellitus.